A detailed history of Jpmorgan Chase & CO transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 18,057 shares of BMEA stock, worth $159,623. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,057
Previous 23,799 24.13%
Holding current value
$159,623
Previous $355,000 77.18%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$4.14 - $15.3 $23,771 - $87,852
-5,742 Reduced 24.13%
18,057 $81,000
Q1 2024

May 10, 2024

SELL
$13.92 - $19.5 $47,982 - $67,216
-3,447 Reduced 12.65%
23,799 $355,000
Q4 2023

Feb 12, 2024

SELL
$8.37 - $19.8 $1.03 Million - $2.44 Million
-123,141 Reduced 81.88%
27,246 $395,000
Q3 2023

Nov 14, 2023

BUY
$13.44 - $23.02 $138,270 - $236,829
10,288 Added 7.34%
150,387 $2.07 Million
Q2 2023

Aug 11, 2023

SELL
$21.66 - $41.8 $537,168 - $1.04 Million
-24,800 Reduced 15.04%
140,099 $3.08 Million
Q1 2023

May 11, 2023

SELL
$6.8 - $32.35 $237,408 - $1.13 Million
-34,913 Reduced 17.47%
164,899 $5.11 Million
Q4 2022

Feb 13, 2023

SELL
$6.3 - $11.6 $184,067 - $338,917
-29,217 Reduced 12.76%
199,812 $1.68 Million
Q3 2022

Nov 14, 2022

SELL
$9.51 - $13.61 $426,960 - $611,034
-44,896 Reduced 16.39%
229,029 $2.24 Million
Q2 2022

Aug 11, 2022

BUY
$3.0 - $12.03 $769,629 - $3.09 Million
256,543 Added 1475.91%
273,925 $3.28 Million
Q1 2022

May 11, 2022

BUY
$4.39 - $9.03 $12,182 - $25,058
2,775 Added 19.0%
17,382 $77,000
Q4 2021

Feb 10, 2022

BUY
$7.22 - $12.72 $55,702 - $98,134
7,715 Added 111.94%
14,607 $109,000
Q3 2021

Nov 12, 2021

BUY
$10.0 - $15.99 $68,920 - $110,203
6,892 New
6,892 $83,000

Others Institutions Holding BMEA

About Biomea Fusion, Inc.


  • Ticker BMEA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,290,600
  • Market Cap $259M
  • Description
  • Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...
More about BMEA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.